Magnitude of rater differences in assessment scales for schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 607-611

  Suzuki, Takefumi ^a,b   Takeuchi, Hiroyoshi ^a   Nakajima, Shinichiro ^a   Nomura, Kensuke ^a   Uchida, Hiroyuki ^a,b   Yagi, Gohei ^a   Watanabe, Koichiro ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

assessment; interrater reliability; PANSS; rater differences; schizophrenia; validity

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CORRELATION COEFFICIENT; DISEASE SEVERITY; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING SCALE; HUMAN; INTERRATER RELIABILITY; MENTAL DISEASE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM;

HUMANS; OBSERVER VARIATION; PHYSICIAN'S ROLE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 77957273380     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f0bae1     Document Type: Article

References (12)

1. Suzuki T, Uchida H, Nomura K, et al. Novel rating scales for schizophreniaVTargeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res. 2008;106: 328-336.
2. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13: 261-276. (Pubitemid 18039085)
3. Guy W. ECDEU Assessment Manual for PsychopharmacologyVRevised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976: 218-222.
4. Nakajima S, Uchida H, Suzuki T, et al. An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia. J Clin Psychopharmacol. 2007;27: 401-403. (Pubitemid 47075516)
5. Suzuki T, Uchida H, Watanabe K, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2008;23: 455-463.
6. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol. 2008;28: 540-543.
7. Nakajima S, Ishida T, Akaishi R, et al. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review. J ECT. 2009;25: 178-181.
8. Suzuki T, Uchida H, Takeuchi H, et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009;24: 628-638.
9. Uchida H, Suzuki T, Mamo DC, et al. Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry Clin Neurosci. 2009;63: 244-246.
10. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009;119(s438): 7-14.
11. Rabinowitz J, Mehnert A, Eerdekens M. To what extent do the PANSS and CGI-S overlap? J Clin Psychopharmacol. 2006; 26: 303-307. (Pubitemid 43804622)
12. Suzuki T, Uchida H, Watanabe K, et al. Treatment target in schizophrenia: a critical review and a clinical suggestion. Psychopharmacol Bull. 2008;41: 80-101.